Kura Oncology (KURA) Total Liabilities (2010 - 2026)

Kura Oncology (KURA) has 17 years of Total Liabilities data on file, last reported at $544.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 43.58% year-over-year to $544.7 million in Q1 2026; TTM through Mar 2026 was $544.7 million, a 43.58% increase from a year earlier, with the FY2025 full-year figure at $564.2 million, up 62.83% from the prior year.
• Total Liabilities for Q1 2026 stood at $544.7 million, down from $564.2 million in the prior quarter.
• Over the last five years, Total Liabilities for KURA reached as high as $564.2 million in Q4 2025 and fell as low as $21.9 million in Q2 2022.
• Historically, Total Liabilities has averaged $178.9 million across 5 years, with a median of $49.0 million in 2024.
• Across the five-year window, Total Liabilities sank 34.84% in 2022 and jumped 676.99% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $36.0 million in 2022, then jumped by 43.39% to $51.7 million in 2023, then surged by 570.74% to $346.5 million in 2024, then soared by 62.83% to $564.2 million in 2025, then declined by 3.47% to $544.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $544.7 million in Q1 2026, $564.2 million in Q4 2025, and $406.8 million in Q3 2025.